MT-1207

Uses your system voice; voice and rate in settings.

Snapshot

≈ 1 min read

Names in other languages

No names in other languages are held for this entry yet.

Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.

MT-1207 is a combined serotonin 5-HT 2A receptor antagonist, α 1 -adrenergic receptor antagonist, and calcium channel blocker which is under development for the treatment of hypertension (high blood pressure). It is taken orally. The drug's time to peak levels is 0.5 to 1.25 hours and its elimination half-life is 4 to 7 hours. MT-1207 is under development in China. As of 2025, MT-1207 has reached phase 2 clinical trials.

MT-1207 is a combined serotonin 5-HT 2A receptor antagonist, α 1 -adrenergic receptor antagonist, and calcium channel blocker which is under development for the treatment of hypertension (high blood pressure). It is taken orally. The drug's time to peak levels is 0.5 to 1.25 hours and its elimination half-life is 4 to 7 hours. MT-1207 is under development in China. As of 2025, MT-1207 has reached phase 2 clinical trials.

Text derived from https://en.wikipedia.org/w/index.php?oldid=1356186296 under CC BY-SA 4.0; modifications have been made.

Sources cited in this revision

3 named source(s) extracted from the cited revision. A source with no author is shown by its publication; nothing is invented.